跳至主要内容
临床试验/NCT01595932
NCT01595932已完成4 期

Efficacy and Tolerability of α-galactosidase in Treating Gas-related Symptoms in Children. A Randomized, Double-blind, Placebo-controlled Trial

Azienda Policlinico Umberto I0 个研究点目标入组 52 人开始时间: 2009年6月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
52
主要终点
Efficacy

研究概览

简要总结

The aim of this study was to evaluate the efficacy and tolerability of α-galactosidase in pediatric patients with predominant gas-related symptoms.

详细描述

Most patients with functional gastrointestinal disorders complain of gas-related symptoms which can negatively affect quality of life, even in pediatric age.

Dietary and life-style changes, administration of simethicone, activated charcoal and probiotics may reduce intestinal gas but often results are unsatisfactory.

Literature shows that α-galactosidase is effective to reduce gas production and related symptoms in adults.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
4 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者
否

入选标准

  • •pediatric out-patients with gas-related disturbances at least once per week over the last 12 weeks.

排除标准

  • •suspected episodes of hypersensitivity or allergy;
  • •chronic organic disorders (by clinical history, physical examination, laboratory tests);
  • •use of drug affecting the GI motility during the previous 4 weeks;
  • •inability of the parent to comprehend the full nature and purpose of the study and unwillingness to co-operate with the Investigator.

研究组 & 干预措施

placebo

Placebo Comparator

干预措施: Placebo (Dietary Supplement)

α-galactosidase

Experimental

干预措施: α-galactosidase (Dietary Supplement)

结局指标

主要结局

Efficacy

时间窗: 5 weeks of observation

Global distress associated with gas-related symptoms (bloating, flatulance, abdominal distension and abdominal spasm): data collected by parents or patients on a daily diary chart, 3 time/daily by using a validated visual score scale (Faces Pain Scale-Revised).

次要结局

  • Efficacy(5 weeks of observation (baseline: 1 week; treatment: 2 weeks; follow-up: 2 weeks))
  • Clinical tolerability(treatment: 2 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Giovanni Di Nardo

MD

Azienda Policlinico Umberto I

相似试验